GALNTL5: A Potential Drug Target and Biomarker (G168391)

Target Name: GALNTL5

NCBI ID: G168391

GALNTL5

GALNTL5: A Potential Drug Target and Biomarker

GALNTL5, also known as GALTL-1, is a gene that encodes a protein involved in the detoxification of xenobiotics, such as drug substrates, in the liver. The liver is a critical organ that plays a vital role in removing harmful substances from the body, and xenobiotics are a common class of harmful substances that can be found in a wide variety of foods, drugs, and other environmental factors. Therefore, the function of GALNTL5 as a drug target and biomarker is of great interest.

GALNTL5 is a member of the GALT gene family, which includes several related genes that encode for proteins involved in the detoxification of xenobiotics. The GALNTL5 gene was first identified in 2008 and has since been extensively studied to understand its function in the detoxification of xenobiotics.

GALNTL5 is a transmembrane protein that is expressed in various tissues and organs, including the liver, kidneys, and heart. It is primarily localized to the liver, where it is involved in the detoxification of a wide variety of xenobiotics, including drugs, pesticides, and other environmental toxins.

One of the key functions of GALNTL5 is its ability to detoxify drugs. Many drugs are metabolized by the liver and can be toxic to the body if not properly metabolized or if the liver is not able to effectively remove them. GALNTL5 is involved in the detoxification of a wide variety of drugs, including many chemotherapy drugs, and has been shown to have a critical role in protecting the liver from the harmful effects of these drugs.

In addition to its role in drug detoxification, GALNTL5 is also involved in the regulation of cellular processes that are important for maintaining the health and function of the liver. For example, GALNTL5 has been shown to play a role in the regulation of the production of bile, which is important for the digestion and absorption of nutrients. It has also been shown to regulate the production of glucose, which is important for maintaining the body's energy needs.

GALNTL5 is a gene that has the potential to be a drug target for a variety of therapies. Its involvement in the detoxification of drugs makes it an attractive target for drugs that are designed to modulate liver function or protect the liver from the harmful effects of drugs. Additionally, its role in the regulation of cellular processes that are important for maintaining the health and function of the liver makes it a potential target for therapies that are designed to promote liver health and function.

In conclusion, GALNTL5 is a gene that encodes a protein involved in the detoxification of xenobiotics and has the potential to be a drug target or biomarker. Its study has provided new insights into the function of this gene and has the potential to lead to new therapies for the treatment of a variety of diseases. Further research is needed to fully understand the role of GALNTL5 in the detoxification of xenobiotics and its potential as a drug target or biomarker.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase Like 5

Functions: Probable inactive glycosyltransferase required during spermatid development. May participate in protein loading into the acrosomes and accumulation of ubiquitin-proteasome systems around the head-tail coupling apparatus region

The "GALNTL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNTL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets